Enlaza Therapeutics, a biotech startup incubated by Avalon Ventures, has successfully raised a total of $161 million to advance its pioneering platform for developing the world's first irreversible, covalent biologic drugs. The company, which is based in San Diego and was established three years ago, is preparing to enter clinical trials with this substantial funding. Notably, the firm has received backing from major entities including JP Morgan and Regeneron. Additionally, Enlaza has secured a $96 million Series A funding round with participation from Lightspeed, highlighting the significant interest and potential in their innovative biologics platform. CEO Sergio Duron is leading the company towards these clinical advancements. Furthermore, Pappas Capital has also announced its investment in Enlaza Therapeutics.